A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Inclusion criteria

• Female and male participants aged 18 to 80 years (inclusive) at the time of informed consent,

• Diagnosis of ulcerative colitis (UC) ≥3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report,

• Inadequate response, loss of response, or intolerance to treatment with biologic/targeted therapy or termination of treatment with biologic/targeted therapy for any other reason,

• Female participants of childbearing potential must be ready and able to use highly effective methods of birth control and male participants are required to use condoms,

• Further inclusion criteria apply.

Exclusion criteria

• Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis, or Crohn's disease (CD),

• Findings suggestive of CD (e.g. fistulae, granulomas on biopsy),

• Evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed,

• Gastrointestinal neoplasia, primary sclerosing cholangitis, or known colonic stricture,

• Evidence of fulminant colitis or toxic megacolon at screening,

• Current ileal-pouch anal anastomosis, ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine,

• Previous surgery or anticipated surgical intervention for UC (trial participants with previous colonic surgery may be allowed based on investigator's judgement after discussion with the sponsor),

• Any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to first trial drug administration and are not anticipated to require surgery,

• Further exclusion criteria apply.